Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...

Roche is working closely with national health systems in Europe to ensure people with multiple sclerosis can access OCREVUS SC as quickly as possible Basel, 25 June 2024 - Roche (SIX: RO, ROG; OTCQX: ...

– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...

Maruho Co., Ltd. announces that it has launched Mitchga subcutaneous (SC) injection 30mg vials (Japanese Accepted Name (JAN): Nemolizumab (genetical recombination), in Japan for the treatment of the ...

The U.S. FDA approved Merck & Co. Inc.’s Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection on Sept. 19, making it the first and only subcutaneously (SC)-administered immune ...